Dr. Saven is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10666 N Torrey Pines Rd
La Jolla, CA 92037Phone+1 858-554-8788Fax+1 858-554-8946
Education & Training
Scripps Clinic/Scripps Green HospitalFellowship, Medical Oncology, 1987 - 1990
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 1984 - 1987
University of Cape Town Faculty of MedicineClass of 1982
Certifications & Licensure
CA State Medical License 1986 - 2025
PA State Medical License 1985 - 1990
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2005-2014
- Top Doctors:San Diego Area Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia Start of enrollment: 2009 Jan 01
- BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
- Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia Start of enrollment: 2022 Mar 02
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Detangling the Threads of Hairy Cell Leukemia, Beyond the Morphology and Into the Molecular.Danielle Brazel, David Hermel, Pranav Gandhi, Alan Saven
Clinical Lymphoma, Myeloma & Leukemia. 2024-09-01 - 5 citationsHairy cell leukemia variant and WHO classification correspondence Re: 5edition WHO classification haematolymphoid tumors: lymphoid neoplasms.Michael Grever, Leslie Andritsos, Mirela Anghelina, Evgeny Arons, Versha Banerji
Leukemia. 2024-07-01 - 12 citationsLong-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.Shivani Handa, Jeong-Ok Lee, Andriy Derkach, Richard M Stone, Alan Saven
Blood. 2022-12-22
Lectures
- Oncology Update 2013Scripps Conference Services & CME /Scripps Translational Science Institute (STSI), San Francisco, Ca - 7/27/2013
- Oncology Update 2013Scripps Conference Services & CME /Scripps Translational Science Institute (STSI), La Jolla, Califor - 7/13/2013
- Scripps Cancer Center’s 33rd Annual Conference: Clinical Hematology and OncologyScripps Conference Services & CME /Scripps Translational Science Institute (STSI), San Diego, Califo - 2/16/2013
Grant Support
- Activated C Protein Resistance As An Operative Risk For Venous ThrombosisNational Center For Research Resources1998–1999
- 2cda Injection In Two Formulations For Advanced MalignanciesNational Center For Research Resources1997
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
